PE20221279A1 - Derivados terapeuticos de interleucina-22 - Google Patents

Derivados terapeuticos de interleucina-22

Info

Publication number
PE20221279A1
PE20221279A1 PE2022000734A PE2022000734A PE20221279A1 PE 20221279 A1 PE20221279 A1 PE 20221279A1 PE 2022000734 A PE2022000734 A PE 2022000734A PE 2022000734 A PE2022000734 A PE 2022000734A PE 20221279 A1 PE20221279 A1 PE 20221279A1
Authority
PE
Peru
Prior art keywords
diacid
protein
fatty acid
linker
interleukin
Prior art date
Application number
PE2022000734A
Other languages
English (en)
Inventor
Kristian Sass-Ørum
Rasmus Jørgensen
Sebastian Beck Jørgensen
Henning Thøgersen
Thomas Hoeg-Jensen
Michael Paolo Bastner Sandrini
Original Assignee
Cytoki Pharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytoki Pharma Aps filed Critical Cytoki Pharma Aps
Publication of PE20221279A1 publication Critical patent/PE20221279A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un derivado de IL-22 que comprende un acido graso unido de forma covalente a una proteina IL-22, donde el acido graso se une de forma covalente a la proteina IL-22 mediante un enlazador y el acido graso es: (i) de la Formula I: HOOC-(CH2)x-CO- , donde x es un numero entero en el intervalo de 10-18, opcionalmente 12-18, 14-16 o 16-18, y designa un punto de union a la proteina IL-22 o enlazador; (ii) un diacido graso; (iii) un diacido C12, C14, C16, C18 o C20; (iv) un diacido C16 o C18; y/o (v) un diacido C18. La proteina de IL-22 es IL-22 humana nativa madura (hIL-22; SEQ ID NO: 1) o una variante de esta. Tambien esta referida a una composicion farmaceutica. Dichos derivados de IL-22 son utiles en el tratamiento de enfermedades metabolicas, hepaticas, pulmonares, renales, entre otras.
PE2022000734A 2019-11-07 2020-11-09 Derivados terapeuticos de interleucina-22 PE20221279A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19207766.7A EP3819307A1 (en) 2019-11-07 2019-11-07 Therapeutic derivatives of interleukin-22
PCT/EP2020/081523 WO2021089875A1 (en) 2019-11-07 2020-11-09 Therapeutic derivatives of interleukin-22

Publications (1)

Publication Number Publication Date
PE20221279A1 true PE20221279A1 (es) 2022-09-05

Family

ID=68502950

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000734A PE20221279A1 (es) 2019-11-07 2020-11-09 Derivados terapeuticos de interleucina-22

Country Status (15)

Country Link
US (3) US11806403B2 (es)
EP (2) EP3819307A1 (es)
JP (2) JP2023502005A (es)
KR (1) KR20220097921A (es)
CN (1) CN114761422A (es)
AU (1) AU2020378648A1 (es)
BR (1) BR112022008497A2 (es)
CA (1) CA3160338A1 (es)
CL (1) CL2022001185A1 (es)
CO (1) CO2022005889A2 (es)
CR (1) CR20220249A (es)
IL (1) IL292657A (es)
MX (1) MX2022005547A (es)
PE (1) PE20221279A1 (es)
WO (1) WO2021089875A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3819307A1 (en) 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
WO2021207662A1 (en) * 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
IL297187A (en) * 2020-04-17 2022-12-01 Univ Leland Stanford Junior Transgenic interleukin-22 polypeptides and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR106F (es) 1964-12-21
WO2011154349A2 (en) 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
MX345608B (es) 2010-12-22 2017-02-07 Baxalta Inc Materiales y metodos para conjugar un derivado de acido graso soluble en agua a una proteina.
MX368005B (es) 2013-03-15 2019-09-13 Genentech Inc Polipéptidos de il-22 y proteínas de fusion de il-22 fc y métodos de uso.
EP3043824B1 (en) 2013-09-13 2022-07-06 The Scripps Research Institute Modified therapeutic agents and compositions thereof
MA41794A (fr) 2015-03-18 2018-01-23 The California Institute For Biomedical Res Agents thérapeutiques modifiés et compositions associées
MX2018000542A (es) * 2015-07-15 2018-06-27 Protagonist Therapeutics Inc Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias.
EP3661955A4 (en) * 2017-08-03 2021-05-26 Synthorx, Inc. CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP3819307A1 (en) 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22

Also Published As

Publication number Publication date
US20220347304A1 (en) 2022-11-03
EP4055035A1 (en) 2022-09-14
WO2021089875A1 (en) 2021-05-14
US20230381320A1 (en) 2023-11-30
EP3819307A1 (en) 2021-05-12
CR20220249A (es) 2022-08-19
BR112022008497A2 (pt) 2022-07-26
AU2020378648A1 (en) 2022-06-23
MX2022005547A (es) 2022-07-04
CA3160338A1 (en) 2021-05-14
CN114761422A (zh) 2022-07-15
CL2022001185A1 (es) 2023-02-03
JP7479539B2 (ja) 2024-05-08
IL292657A (en) 2022-07-01
KR20220097921A (ko) 2022-07-08
JP2023502005A (ja) 2023-01-20
JP2023083380A (ja) 2023-06-15
US20240108731A1 (en) 2024-04-04
CO2022005889A2 (es) 2022-07-29
US11806403B2 (en) 2023-11-07

Similar Documents

Publication Publication Date Title
PE20221279A1 (es) Derivados terapeuticos de interleucina-22
AR109461A2 (es) Formulación de anticuerpo anti-cd20 y su uso para preparar un medicamento
CN101809029A (zh) 具有延长目标肽的血浆半衰期作用的肽
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
ECSP088753A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
HRP20170567T1 (hr) Humanizirana protutijela za liv-1 i njihova uporaba za liječenje raka
PE20151205A1 (es) Formulaciones que contienen linaclotida para administracion oral
PE20191492A1 (es) Composicion farmaceutica que comprende selexipag
AR078044A1 (es) Variantes de peptidos natriureticos de tipo c
EA200800050A1 (ru) Самобуферирующиеся композиции белков
HRP20141251T1 (hr) Ekstracelularna hijaluronidaza iz streptomyces koganeiensis
PE20220965A1 (es) Analogos de relaxina y metodos para usarlos
DE602008005155D1 (de) Glp-1-fc fusionsprotein-formulierung
HRP20130933T1 (hr) Pripravci sa smanjenom formacijom dimera
CO2019013768A2 (es) Compuestos de mic-1 y usos de estos
JP2016501866A (ja) 皮下脂肪生成を刺激するペプチド
van der Horst et al. Role of fatty acid-binding protein in lipid metabolism of insect flight muscle
PE20212158A1 (es) Composicion farmaceutica acuosa de anticuerpo anti-il17a y su uso
HRP20161006T1 (hr) Postupak liječenja kožnih poremećaja
EA201070766A1 (ru) Стабильные при комнатной температуре лиофилизированные композиции натрийуретического пептида
WO2017046314A3 (en) Improvement of expression and folding in the manufacturing process of cd-rap by using a cd-rap precursor protein
AR099344A1 (es) Composición nutricional que comprende suero y caseína hidrolizada
MX2021000016A (es) Formulaciones de factor de crecimiento de fibroblastos (fgf-21).
JP2016510315A5 (es)
AR118601A2 (es) Formulaciones sólidas estables de un receptor gc-c, agonista polipeptídico adecuado para administración oral